Uncover The Heart-Mitochondria Connection: Why Cardiac Health Starts at the Cellular Level

A pattern I see regularly in clinic: a patient comes in after a full cardiology workup. Echocardiogram normal. Stress test normal. Bloods unremarkable. They have been told their heart is fine. But they cannot walk up a flight of stairs without their chest feeling heavy. They wake exhausted. Exercise, which used to feel manageable, now wipes them out for days. They are on a statin and have noticed their muscles aching in a way they never did before.

The cardiology report says the heart is structurally sound. What it does not say — because it was never tested — is whether that heart has enough energy to do its job properly.

That is the gap this article addresses. And the answer to it sits not in coronary anatomy but in cellular biology — specifically, in the mitochondria.

Most people think about heart health in terms of cholesterol, blood pressure, and blockages. Those things matter. But they describe the plumbing. They do not describe the engine. The heart beats roughly 100,000 times a day without pause, and that sustained output requires more energy per gram of tissue than almost any organ in the body. That energy comes almost entirely from mitochondria — and when mitochondrial function is impaired, cardiac performance suffers in ways that standard cardiovascular assessment is not designed to detect.

Conventional cardiology has become extraordinarily sophisticated at measuring coronary anatomy, ejection fraction, valve function, and electrical conduction. What it rarely measures is mitochondrial function. The engine goes largely uninvestigated until it has failed badly enough to show up as a diagnosable disease state. Functional medicine investigates it earlier — because mitochondrial dysfunction is a cardiac risk factor. Not a speculative one. A measurable, testable, and addressable one.

The most energy-demanding organ in the body

The heart consumes approximately 6 kg of ATP per day. To put that in context, the entire body contains only around 250 grams of ATP at any given moment. This means the cardiac ATP pool turns over roughly 20 to 30 times daily — a recycling rate that is only possible because the mitochondria in cardiac cells are producing ATP continuously, at near-maximum capacity, around the clock.

Under resting conditions, the heart derives about 60 to 70 percent of its energy from fatty acid oxidation, with the remainder coming from glucose and lactate. During exercise or physiological stress, that ratio shifts — glucose and lactate metabolism increase — but the dependence on mitochondrial oxidative phosphorylation remains constant. The heart cannot run on glycolysis alone. Unlike skeletal muscle, which can tolerate short bursts of anaerobic metabolism, cardiac muscle requires a continuous aerobic energy supply. Interrupt mitochondrial function and you interrupt cardiac function. It is that direct a relationship.

This is the part of the physiology textbook that doesn't make it into standard cardiovascular risk assessment. And it is, clinically, where a lot of unexplained cardiac symptoms — exertional fatigue, reduced exercise tolerance, palpitations without structural cause, post-viral cardiac involvement — begin to make more sense.

What mitochondria actually do in cardiac tissue

Mitochondria are doing several things in the heart simultaneously, and understanding each one matters for the clinical picture.

ATP production via oxidative phosphorylation

The electron transport chain (ETC) — five protein complexes embedded in the inner mitochondrial membrane — converts energy from NADH and FADH2 (produced during fat and glucose oxidation) into ATP. Complex I through Complex IV transfer electrons down a redox gradient, pumping protons across the inner membrane. Complex V (ATP synthase) uses that proton gradient to drive ATP synthesis. The efficiency of this process depends on the integrity of all five complexes, the availability of electron carriers (CoQ10, cytochrome c), and the supply of key cofactors including B vitamins, magnesium, and iron.

In the cardiac context, any disruption to ETC function reduces ATP output. The heart has very limited capacity to buffer this reduction. Even a 20 to 30 percent drop in mitochondrial ATP production can produce measurable impairment in myocardial contractility.

Calcium signalling and contractility

Mitochondria regulate intracellular calcium concentration in cardiomyocytes, which directly controls the force of myocardial contraction. Calcium enters the mitochondrial matrix through the mitochondrial calcium uniporter (MCU) and is released via the Na+/Ca2+ exchanger. This calcium cycling is tightly coupled to ATP production — calcium stimulates key enzymes in the citric acid cycle, increasing NADH generation and ATP output during periods of high demand. When mitochondrial function is impaired, calcium regulation becomes dysregulated, which can contribute to arrhythmia, impaired relaxation (diastolic dysfunction), and in severe cases, cell death.

Reactive oxygen species (ROS) management

A small percentage of electrons in the ETC leak and react with oxygen to form superoxide — reactive oxygen species (ROS). At physiological levels, ROS function as signalling molecules. At elevated levels, they damage mitochondrial DNA, lipid membranes, and proteins, leading to a self-amplifying cycle of mitochondrial dysfunction. Healthy mitochondria maintain antioxidant defences — primarily manganese superoxide dismutase (MnSOD), glutathione peroxidase, and the glutathione system — that keep ROS in check. Depleted antioxidant capacity, whether from chronic oxidative stress, nutrient deficiency, or toxic exposure, allows ROS accumulation and accelerates mitochondrial damage in cardiac tissue.

There is a non-pharmacological intervention worth noting here: red and near-infrared light therapy, specifically photobiomodulation (PBM). PBM wavelengths interact with cytochrome c oxidase — Complex IV of the electron transport chain — in a way that appears to improve electron flow efficiency, reduce electron leak, and therefore reduce ROS production at the source. The mechanism is wavelength and dose-dependent, not a general "light is good" effect. This is an area of active research with a plausible molecular mechanism, and it has direct relevance to cardiac mitochondrial function given that Complex IV is the final and rate-limiting step of oxidative phosphorylation.

Apoptosis regulation

Mitochondria are the gatekeepers of the intrinsic apoptosis pathway. In cardiac tissue, dysregulated mitochondrial apoptotic signalling — particularly via the mitochondrial permeability transition pore (mPTP) — is a central mechanism in ischaemia-reperfusion injury and in the cardiomyocyte loss that characterises heart failure. The mPTP opens under conditions of calcium overload, oxidative stress, and ATP depletion — all of which are downstream consequences of impaired mitochondrial function.

When mitochondrial function fails — what happens to the heart

The relationship between mitochondrial dysfunction and cardiac disease is no longer speculative. It shows up consistently across multiple disease states.

Heart failure

Mitochondrial dysfunction is a central feature of heart failure, not a secondary consequence. The failing heart shows reduced Complex I and Complex III activity, decreased CoQ10 levels, impaired fatty acid oxidation, and increased ROS production. A 2017 review in the Journal of the American College of Cardiology described mitochondrial dysfunction as "a hallmark of the failing heart" and identified it as a potential therapeutic target. The shift from fatty acid oxidation toward glycolysis in the failing heart — sometimes described as a "foetal metabolic reprogramming" — is partly an adaptation to impaired mitochondrial capacity, and it further reduces cardiac efficiency because glucose oxidation generates less ATP per unit of oxygen consumed than fatty acid oxidation.

Diabetic cardiomyopathy

In type 2 diabetes, mitochondrial dysfunction in the heart precedes structural remodelling. Hyperglycaemia drives excess ROS production via the ETC, impairs mitochondrial biogenesis through downregulation of PGC-1α (the master regulator of mitochondrial synthesis), and promotes lipotoxicity as excess fatty acids accumulate in cardiac tissue. People with type 2 diabetes have a two to four times higher risk of heart failure even in the absence of coronary artery disease or hypertension — a risk that is at least partly mitochondrial in origin.

Hypertension and left ventricular hypertrophy

Chronic pressure overload from hypertension increases cardiac workload and energy demand. Mitochondria attempt to compensate through increased ROS production and altered substrate utilisation, but over time mitochondrial biogenesis fails to keep pace with the increased demand. Left ventricular hypertrophy — the structural adaptation to sustained pressure overload — is associated with reduced mitochondrial density relative to cell volume, creating an energy deficit in the hypertrophied tissue.

Post-viral cardiac involvement

This is a presentation I am seeing more frequently in clinic. Post-viral syndromes — including post-COVID cardiac involvement — appear to involve direct mitochondrial damage via multiple mechanisms: viral disruption of ETC complex activity, immune-mediated oxidative stress, and dysregulation of the ACE2 receptor pathway, which plays a role in mitochondrial function in cardiac tissue. Patients present with exertional intolerance, palpitations, and reduced cardiac output that does not resolve with standard management. Mitochondrial support is part of the clinical strategy for this presentation.

The heart doesn't fail because it stops trying. It fails because it runs out of fuel. Mitochondrial dysfunction is the fuel crisis that precedes structural disease — and it is largely invisible to standard cardiovascular assessment.

What drives mitochondrial dysfunction — and why it's common

Mitochondrial dysfunction is not rare. The conditions that produce it are widespread, and most of them are modifiable. Understanding the drivers is what makes this clinically actionable.

The statin-CoQ10 interaction deserves more attention than it gets in clinical practice. Statins are among the most prescribed medications in Australia. They work by inhibiting HMG-CoA reductase — the same enzyme used in the early steps of CoQ10 synthesis. The result is a dose-dependent reduction in endogenous CoQ10 production. CoQ10 is not a peripheral nutrient. It is a structural component of the electron transport chain. Depleting it in a patient with existing cardiovascular risk is not a neutral intervention. The clinical literature on statin-associated myopathy consistently implicates CoQ10 depletion as a contributing mechanism, and several trials have shown that CoQ10 supplementation reduces statin-associated muscle symptoms.

The ROOT Method applied to cardiac energy

When a patient comes to me with cardiac symptoms that have not been fully explained by structural assessment — unexplained fatigue with exertion, reduced exercise tolerance, palpitations with normal ECG, post-viral cardiac symptoms — the standard workup has usually ruled out the most dangerous structural causes. What it has not done is look upstream at energy metabolism.

The clinical question I am always asking is: what is the energy status of this heart? Not just the anatomy, not just the electrical activity — but the actual bioenergetic capacity of the myocardium. That question requires different tests than a standard lipid panel or echocardiogram, and it opens different treatment options.

What we test and why

Functional assessment of mitochondrial function relevant to cardiac health draws on several overlapping panels. These are the tests I use in clinical practice for patients with energy, fatigue, and cardiac performance presentations:

Organic Acids Test (OAT)

The OAT is the most direct functional window into mitochondrial metabolism available outside of a research laboratory. Key markers for cardiac mitochondrial assessment include:

• Krebs cycle intermediates (citrate, isocitrate, aconitate, succinate, fumarate, malate): Elevated or disordered patterns indicate impaired citric acid cycle flux, which reduces NADH and FADH2 availability for the ETC
• ETC markers: Elevated pyruvate with low acetyl-CoA entry markers suggests impaired pyruvate dehydrogenase complex — often B1, B2, lipoic acid, or CoA dependent
• Fatty acid oxidation markers (adipate, suberate, ethylmalonate): Elevated levels indicate impaired mitochondrial fatty acid beta-oxidation — directly relevant given the heart's 60-70% reliance on fatty acids for fuel
• CoQ10 functional proxy markers: Certain OAT patterns are consistent with functional CoQ10 insufficiency even when serum CoQ10 appears borderline
• Oxidative stress markers (8-hydroxy-2-deoxyguanosine): Measures mitochondrial DNA oxidative damage

For patients on statins, the OAT frequently reveals the functional consequence of CoQ10 depletion in a way that serum CoQ10 alone does not capture.

Comprehensive Nutrient and Metabolic Panel

A targeted blood panel for cardiac mitochondrial function goes beyond a standard cardiovascular screen. I am looking at: plasma CoQ10, serum magnesium (or preferably red cell magnesium), B vitamin status (B1, B2, B3, B5), ferritin and iron studies, zinc and manganese, fasting glucose and insulin with HOMA-IR calculation, HbA1c, high-sensitivity CRP, homocysteine, and a full thyroid panel. Thyroid function is included because hypothyroidism directly impairs mitochondrial biogenesis and cardiac contractility — it is one of the most commonly missed metabolic contributors to cardiac dysfunction.

Fatigue and Energy Workup

For patients presenting with the overlap of cardiac symptoms and fatigue — which is frequent — the fatigue workup and the cardiac mitochondrial workup are largely the same investigation. Reduced exercise tolerance, post-exertional malaise, morning fatigue, and poor cardiac reserve all converge on the same upstream biology: impaired mitochondrial ATP production. Treating them as separate problems produces inferior outcomes to treating them as one.

Clinical targets: what the research supports

I want to be specific here, because the supplement market around mitochondrial health is saturated with generic claims. What follows is what the clinical evidence actually supports, at what level of confidence, and for what presentations.

Coenzyme Q10

CoQ10 is the most researched mitochondrial intervention in cardiac medicine, and it has the strongest evidence base. The Q-SYMBIO trial (2014), a multicentre randomised controlled trial published in JACC Heart Failure, randomised 420 patients with severe heart failure to CoQ10 300mg/day or placebo for two years. The CoQ10 group showed a significant reduction in major adverse cardiovascular events (15% vs 26% in placebo), reduced cardiovascular mortality, and improvement in NYHA functional class. This is a hard outcome trial, not a surrogate marker study.

For patients on statins, CoQ10 supplementation in the range of 100-300mg/day is a reasonable clinical intervention based on the pharmacological rationale for statin-induced depletion and the consistent finding of statin-associated muscle symptoms responding to CoQ10 repletion. Dose matters — ubiquinol (the reduced, active form) has superior bioavailability over ubiquinone in most adults over 40.

Magnesium

Magnesium is required for over 300 enzymatic reactions, including every step that involves ATP — because the biologically active form of ATP is Mg-ATP. It is also essential for the function of several ETC enzymes and for maintaining the mitochondrial membrane potential. Magnesium deficiency is common in Australia — surveys consistently show intake below recommended levels across most adult age groups — and it is poorly captured by serum magnesium, which is a late and insensitive marker of intracellular deficiency. Red cell magnesium or intracellular magnesium testing is more clinically useful. Cardiac relevance: magnesium deficiency is independently associated with increased cardiovascular risk, arrhythmia, hypertension, and impaired insulin sensitivity.

NAD+ precursors (NMN, NR)

NAD+ (nicotinamide adenine dinucleotide) is a central electron carrier in the ETC and a substrate for sirtuins — a family of proteins that regulate mitochondrial biogenesis, DNA repair, and metabolic function. NAD+ levels decline with age, with chronic inflammation, and with oxidative stress. In cardiac tissue, reduced NAD+ availability impairs ETC efficiency and reduces the activity of SIRT3 — the primary mitochondrial sirtuin — which regulates multiple aspects of cardiac metabolism including fatty acid oxidation, ROS management, and the mPTP. Preclinical data on NMN and NR in cardiac models is compelling. Human trial data is accumulating but not yet at the level of the CoQ10 evidence. I use NAD+ precursors in specific presentations — particularly age-related cardiac fatigue and post-viral cardiac involvement — rather than as a blanket recommendation.

L-Carnitine

L-Carnitine transports long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation — a process the heart depends on for 60-70% of its energy supply. L-Carnitine deficiency impairs cardiac fatty acid oxidation directly. A 2013 meta-analysis in Mayo Clinic Proceedings found that L-Carnitine supplementation in the context of acute myocardial infarction was associated with significant reductions in all-cause mortality, ventricular arrhythmias, and angina. The effect is most pronounced where carnitine status is depleted — which is common in patients with chronic illness, renal impairment, or vegetarian/vegan diets.

D-Ribose

D-Ribose is a five-carbon sugar that is the rate-limiting substrate for ATP synthesis via the purine nucleotide pathway. In ischaemic or metabolically stressed cardiac tissue, ATP depletion can persist for days after the acute event because the resynthesis pathway is slow. D-Ribose accelerates ATP repletion in cardiac tissue and has been studied in ischaemic heart disease, heart failure, and chronic fatigue with cardiac involvement. The evidence base is smaller than CoQ10 but the mechanistic rationale is sound and the safety profile is excellent. I use it as a targeted intervention in cardiac fatigue presentations where ATP depletion is the suspected limiting factor.

Exercise as mitochondrial medicine

No supplement replicates the mitochondrial biogenesis signal generated by exercise. PGC-1α — the master regulator of mitochondrial synthesis — is activated primarily by exercise-induced energy depletion (via AMPK) and calcium signalling from muscle contraction. High-intensity interval training (HIIT) produces a stronger mitochondrial biogenesis signal than steady-state moderate exercise, though both have benefit. The clinical evidence for exercise-based cardiac rehabilitation in heart failure, post-infarction, and metabolic heart disease is among the strongest in cardiovascular medicine. Structured exercise is not optional in a mitochondrial cardiac protocol — it is the primary intervention.

Infrared therapy and heat stress as a mitochondrial input

Heat therapy — particularly far-infrared sauna — works as a hormetic stressor in a similar mechanistic family to exercise, though through different pathways. Controlled heat exposure raises core body temperature, triggering the production of heat shock proteins (HSPs). A single far-infrared session has been shown to increase circulating HSP70, and controlled heat stress studies have shown HSP72 increases of around 49% following passive heat exposure. HSPs function as molecular chaperones — they protect cellular proteins from misfolding under stress, help clear damaged proteins, and support cellular resilience. In cardiac tissue specifically, HSPs are protective against ischaemia-reperfusion injury.

Beyond HSPs, consistent thermal therapy — distinct from a single hot shower — has been associated with improved endothelial function and vascular dilation in multiple clinical reviews. The endothelium is not passive plumbing. It regulates vascular tone, inflammatory signalling, and clotting balance. Endothelial dysfunction is an early and measurable feature of cardiovascular risk, and heat-induced improvements in endothelial function represent a plausible non-pharmacological contribution to cardiac resilience.

The Finnish sauna epidemiology data from Laukkanen and colleagues is worth mentioning here. In a large prospective cohort, men using sauna four to seven times per week had a 63% lower risk of sudden cardiac death and a 50% lower risk of cardiovascular mortality compared with once-weekly users. The mechanisms are likely multiple — vascular adaptation, autonomic nervous system training, reduced inflammatory burden — and the mitochondrial pathway is one plausible contributor.

A practical note on delivery: traditional saunas heat the ambient air to very high temperatures. Far-infrared saunas heat the body directly via thermal radiation at lower ambient temperatures, which makes consistent, repeated use more tolerable for people with cardiovascular conditions who find extreme heat poorly tolerated. Consistency matters more than intensity here — the biological benefits require repeated adaptive exposure, not a single maximal session. Sessions of 15 to 20 minutes with adequate hydration and a cooldown period are the standard clinical recommendation. People with existing heart conditions, autonomic dysfunction, or those on medications affecting thermoregulation should consult their clinician before starting.

I recommend infrared sauna as an adjunct intervention in mitochondrial cardiac protocols — not as a replacement for exercise, diet, or targeted supplementation, but as an additional hormetic input that operates through complementary pathways. It is a tool, not a treatment. Used consistently and appropriately, it adds biological value to an otherwise well-structured protocol.

Where to start if this resonates

The clinical picture I have described here applies to a broader range of people than those with diagnosed heart disease. If you have unexplained fatigue that worsens with exertion, reduced exercise tolerance that has developed gradually over years, palpitations with a structurally normal heart, or a history of statin use without CoQ10 supplementation — these are presentations where mitochondrial function is worth investigating.

The first question worth asking is whether your current workup has actually assessed the right things. A normal echocardiogram and a normal stress test tell you the heart is structurally intact and not acutely ischaemic. They say nothing about the energy status of the myocardium, the CoQ10 and nutrient cofactor availability for the ETC, the degree of mitochondrial oxidative stress, or the metabolic flexibility of the cardiac substrate utilisation. That is a significant gap.

The second question is whether any of the modifiable drivers in the table above apply to your situation. Statin use without CoQ10. Longstanding insulin resistance. Low dietary quality and sedentary behaviour. Chronic psychological stress. These are not abstract risk factors. They are direct inputs into mitochondrial function, and addressing them produces measurable changes in cardiac energy metabolism.

The third is getting a clinical assessment from someone who understands bioenergetics as a cardiac framework, not just coronary anatomy. The questions that matter in this context — about energy production, substrate utilisation, nutrient status, oxidative load — are not the ones that typically get asked in a standard cardiology or GP appointment. They require time, a different set of tests, and a clinical framework built around cellular function rather than organ-level pathology.

The clinical case for taking mitochondria seriously

Cardiovascular medicine has made genuine progress over the past 50 years. Acute MI mortality has fallen dramatically. Surgical interventions for structural disease are sophisticated. Antihypertensive and lipid-lowering pharmacology has reduced population-level event rates.

What it has not done is address the energy biology of the heart. Heart failure rates continue to rise globally. Metabolic cardiomyopathy is increasingly prevalent. Post-viral cardiac presentations represent a new clinical challenge that standard cardiology frameworks are not fully equipped to handle. And statin-induced mitochondrial disruption in a population with existing cardiovascular risk remains systematically under-addressed.

The mitochondria are not a niche interest. They are the reason the heart beats. Investigating their function, identifying what is impairing it, and supporting their recovery is not alternative medicine. It is the next frontier of cardiac care — and the functional medicine framework gives us both the testing tools and the clinical rationale to act on it now, rather than waiting for it to become standard of care.

Frequently asked questions

Related reading: Chronic fatigue and mitochondrial function  |  Functional diagnostic testing Melbourne  |  Book a discovery call

Disclaimer: This article is for educational purposes and does not constitute medical advice. If you are experiencing cardiac symptoms, please seek assessment from a qualified medical practitioner. This content is prepared by Domenic Pisanelli, naturopath and functional medicine practitioner (ATMS registered), at Vital Health and Natural Medicine, Kealba VIC 3021. Phone: 03 9382 9790.